Released Mar 9, 2023, before the open
10-K filed Mar 9, 2023, 68 days after period end · 0001628280-23-007297
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.18M$4.18M derived+486.8% vs Q4 2021−36.9% vs Q3 2022
Net Income-$28.89M-$28.89M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$31,886,000N/M
Operating Cash Flowderived-$28,924,000N/M
Free Cash Flowderived-$29,193,000N/M
Margins · derived
Operating margin-762.1%+3176.5 pt vs Q4 2021
Net margin-690.4%+3397.0 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $4.18M | $713.00K | $251.00K | — |
| Net Income | -$28.89M | -$29.14M | -$20.76M | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR